Indlela yokusebenzisa i-RU486 (i-Pill Pill)

Yintoni ongayilindela kwiCandelo loNyango lweZonyango zokuThathela isisu

I-RU486 (igama elithi brand Mifeprex) liye lasetyenziswa ngokubanzi, ngokufanelekileyo, kwaye lisetyenziswe ngokukhuselekileyo eFransi, eSweden naseBrithani iminyaka. Iphilisi yokukhupha i-RU486 nayo ivunyiwe yi-FDA e-US. Iphilisi yokukhipha isisu (ikwajongwa njengento yokukhupha isisu) kufuneka inikezwe ngumqeqeshi wezempilo.

Ukuze ube nesisu sokukhupha isisu, kuya kufuneka uhambele umboneleli wakho wezempilo.

Inxalenye yokuqala yokukhipha isisu kuthatha ipilisi yokukhipha isisu RU486. Emva koko, ukuba kuyimfuneko, i-RU486 kufuneka ilandelwe kunye neyeza lesibini, i-misoprostol, ukuphelisa ngokupheleleyo ukukhulelwa.

Ookuqala u-RU486 ukonyulwa

Ngethuba lokutyelela, umboneleli wakho wezempilo kufuneka aqale ukugqiba ukuba ukhulelwe (ngokuvavanya ukukhulelwa kunye / okanye kunye nokuhlolwa kwe-pelvic). Ukuba ukhulelwe, ugqirha wakho unokuqalisa umhla wokukhulelwa ngokusebenzisa i-sonogram (ekubeni oku akuyiyo i-FDA-egunyazisiweyo, abanye ababoneleli bangakhetha ukungenzi i-sonogram).

Uya kunikwa iipilisi ezintathu (200 mg nganye) ye-Mifeprex (RU-486) ​​ukuba ithathwe ngokukhawuleza ngomlomo. Le dose ye mifepristone iya kubangela ukuba iqanda elixutywe ngumhlaza lingakwazi ukuhlala linyamekele kwicala lombeleko.

Uza kulungelelanisa ukuqeshwa kwakho okulandelayo ukuba kwenzeke iintsuku ezimbini emva koko.

Ukhetho lwesiBini

Ngethuba lokutyelela (okufuneka kube ngamahora angama-48 emva kokuba uthathe i-mifepristone), ugqirha wakho uya kwenza uvavanyo ukuba abone ukuba ukhulelwe.

Ukuba akunjalo, uya kunikwa iyeza lesibini, i-misoprostol, ngendlela yeepilisi ezimbini eziza kuthathwa ngomlomo okanye njenge-vaginal suppository. La mayeza kufuneka athathwe kwiofisi yegqirha kwaye kufuneka enze ukukhulelwa kuphele naphi kwiiyure ezintandathu ukuya kweveki kamva.

I-misoprostol iya kubangela iinqununu ze-uterine, ngoko unako ukuxinwa kunye nokuphuma kwegazi.

Ugqirha wakho unokumisela iyeza zentlungu kwaye akunike izikhokelo xa kwenzeka imeko engxamisekileyo.

Utyunjwa lokugqibela

Kufuneka ulandele uhambo lwakho lokutyelela ugqirha ezimbini kwiiveki emva kokuthatha i-misoprostol. Ngeli xesha, ugqirha uya kugqiba ukuba ukukhulelwa kuphelile kwaye kuqinisekiswe ukuba akukho zinkathazo (ezifana nokugaya okanye ukusuleleka). Ukuba kunqunywe ukuba usakhulelwe, kuya kucetyiswa ukuba ucebise inkqubo yokuhlinzwa ukuphelisa ukukhulelwa. Ngokutsho kwelebula leMifeprex, "Izigulane ezinokukhulelwa okuqhubekayo kule tyelelo zinomngcipheko we-fetal malformation ngenxa yonyango. Ukupheliswa kokupheliswa kukucetyiswa ukulawula ukuphulwa kwesisu sokukhupha isisu. "

Okunye malunga nePilisi yokuKhipha isisu

Xa kuthathwa yodwa, ipilisi yokukhupha i-RU486 ibangela ukukhipha isisu ngokupheleleyo malunga neepesenti ezingama-64 ukuya kuma-85 ekhulwini kwixesha. Xa i-misoprostol inikezelwa iiyure ezingama-48 kamva, ukuphumelela kokukhipha isisu kunyuke kwi-92% ukuya kwi-98 ekhulwini.

Imiphumo yecilisi yemiphumo yokufaka isisu ingabandakanya ukutyunjwa, isisulu sokuncwina, ukuhlanza kunye nesifo sohudo, kunye nokuphuma kwamanzi okungapheli iintsuku ezisibhozo ukuya kwi-10.

Iphilisi yokukhupha i-RU486 yi-FDA kuphela evunyelwe ukuba ibhinqa elifikelela kwiiveki ezisixhenxe ezikhulelwe (ezilingana neeveki ezintlanu ukususela ekukhulelwe) okanye ukuya kwiintsuku ezingama-49 emva kokuhamba kwexesha lokugqibela.

Nangona abanye ababoneleli bezempilo baya kusetyenziswa le ndlela kubasetyhini ngaphezu kweeveki ezisibhozo ezikhulelweyo, sebenzisa ngeli xesha liqwalasela i-ilebhu (ithetha, kungekhona i-FDA ivunyiwe).

Nangona kukho inkolelo eninzi, kubalulekile ukuba uqaphele ukuba uMbutho wezeMpilo waseMelika ufumene ukuba akukho bukho ubungqina bokuthi ukukhipha isisu kubangelwa yimpilo yengqondo .

Imithombo:

FDA. Ilebula leMifeprex . Fi kelelwa ngo 5/12/08.

Spitz, IM, Bardin, CW, Benton, L. & Robbins, A. (1998). Ukuphela kokukhulelwa kwangaphambili kunye ne-mifepristone kunye ne-misoprostol e-United States. I-New England Journal of Medicine, 338 (18) , 1241-47. Kufumaneka ngokubhalisa ngasese 5/12/08